EN | UA
EN | UA

Help Support

Back

Darunavir-cobicistat vs. lopinavir-ritonavir to treat COVID-19 pneumonia

lopinavir-ritonavir lopinavir-ritonavir
lopinavir-ritonavir lopinavir-ritonavir

What's new?

Compared to darunavir-cobicistat, lopinavir-ritonavir was related to a shorter time to virological clearance and faster clinical improvement in COVID-19 patients.

A recent retrospective proof of concept study (DOLCI) published in "PLOS ONE" revealed that early treatment with lopinavir-ritonavir + standard of care was linked with shorter time to virological clearance and expedited clinical improvement than darunavir-cobicistat in patients hospitalized with SARS-CoV-2 pneumonia.

This multicenter observational study was performed to assess the safety and effectiveness of darunavir-cobicistat [800 mg darunavir/ 150 mg cobicistat 1 tablet orally once daily) in contrast to lopinavir-ritonavir (200 mg lopinavir/ 50 mg ritonavir 2 tablets orally twice daily) for COVID-19 management.

Overall, 400 adult participants who received darunavir-cobicistat (n = 100) or lopinavir-ritonavir (n= 300) for a minimum of 3 days as part of their COVID-19 intervention were involved and analyzed. From the electronic medical records of participants, collection of data was done. The composite endpoint of time to clinical improvement and/or SARS-CoV-2 clearance was the key endpoint ascertained.

As found, 92.5% of patients were male with a mean time from onset of symptoms to initiation of the therapy of 7.57 days. In contrast to individuals who were given darunavir-cobicistat, individuals who were given lopinavir-ritonavir exhibited a shorter time to virological clearance and/or clinical improvement (composite primary outcome). Lopinavir-ritonavir treated people exhibited a slower time to virological clearance and hastened time to clinical improvement than darunavir-cobicistat, as shown in Table 1:

The safety profile of both the protease inhibitors was comparable since no profound inter-group differences in the occurrence of side effects were witnessed. Hence, lopinavir-ritonavir therapy is effective and safe to shorten time to virological clearance and accelerate clinical improvement in coronavirus-infected people.

Source:

PLOS ONE

Article:

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: